TLC News and Press, Taiwan Liposome Company Ltd. From 07/05/21

TAIPEI, Taiwan, July 05, 2021 (GLOBE NEWSWIRE) -- Taiwan Liposome Company (Nasdaq: TLC, TWO: 4152, “the company”), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced details of the company...

Taiwan Liposome (TLC) and Zydus Healthcare have signed a license supply and commercialization agreement for AmphoTLC (Amphotericin B Liposome for Injection 50mg) in India.AmphoTLC is indicated for severe systemic fungal infections such as mucormycosis. Under the terms of the agreement, T...

Larimar Therapeutics (LRMR) -40% after FDA puts clinical hold on CTI-1601 program.GSX Techedu (GOTU) -15% after Q1 earnings releaseCarLotz (LOTZ) -16% after losing key sourcing partner temporarily.Travere Therapeutics (TVTX) -13% on sparsentan developme...

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 26, 2021 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, and Zydus Healthcare Limited, part of Zydus Cadila g...

Gainers: Flanigan's Enterprises (BDL) +73%.Pieris Pharmaceuticals (PIRS) +48%.RYB Education (RYB) +27%.uCloudlink (UCL) +24%.Friedman Industries (FRD) +23%.Taiwan Liposome (TLC) +19%.Provention Bio (PRVB) +19%.The Joint (JYNT) +18%.New Oriental Education & Technology (EDU) +18%....

AnPac Bio-Medical Science (ANPC) +29% on launching novel Cancer treatment technology and product JV.Pieris Pharmaceuticals (PIRS) +21% on collaboration with Genentech.Ault Global Holdings (DPW) +14% on Q1 results.Taiwan Liposome Company (TLC) +13% as its application for Am...

Taiwan Liposome (TLC) gains 4.3% premarket after in reaction to the announcement that the Central Drugs Standard Control Organization ((CDSCO)) of India has approved the New Drug Application ((NDA)) of Amphotericin B Liposome for Injection 50mg (known as Ampholipad&#x...

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 25, 2021 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that the Central Drugs Standard Control ...

Gainers: Scopus BioPharma (SCPS) +97%.MMA Capital (MMAC) +58%.Aptorum (APM) +37%.Creative Realities (CREX) +33%.Obalon Therapeutics (OBLN) +30%.Regional Health Properties (RHE) +24%.Taiwan Liposome (TLC) +21%.Virgin Galactic (SPCE) +19%.Verastem (VSTM) +18%.Veritiv (VRTV) +17%.Loser...

InspirMed, a subsidiary of Taiwan Liposome (TLC) presents findings from two separate studies in rats on ISPM21 and ISPM19, respectively, as well as from a ISPM19 lung deposition study at the 23rd International Society for Aerosols in Medicine ((ISAM)) Congress.Pharmacokinetic studie...